Full Breakdown
Neko Health Secures $700 Million Series C to Launch U.S. Preventive-Care Clinics
7/16/2026, 11:45:32 AM
Core Funding and Expansion Plan
Neko Health announced a $700 million Series C round led by Lightspeed Venture Partners and co-led by O.G. Venture Partners. The capital will fund the company’s first U.S. clinic in New York later this year, followed by additional locations across the country. Investors include Mark Zuckerberg and Priscilla Chan, Maria Sharapova, Will.i.am, Thierry Henry, Claudia Schiffer, Ari Emanuel, Tim Ferriss, and existing backers such as Atomico, General Catalyst and Lakestar. The round follows a $260 million Series B raised in January 2025.
Background & Context
Founded in 2018 by Spotify co-founder Daniel Ek and Hjalmar Nilsonne, Neko Health opened its inaugural clinic in February 2023. It now operates eight European sites—four in London, two in Stockholm, and additional clinics in Manchester, Birmingham, and other London districts. The company’s “Neko Health Scan” is a 60-minute, non-invasive, radiation-free assessment that combines proprietary imaging hardware with rapid blood analysis and, more recently, body-composition and wearable-data integration.
Key Figures & Groups
- Daniel Ek – Spotify co-founder, chair of defense startup Helsing.
- Hjalmar Nilsonne – Co-founder and CEO, former CEO of energy-data firm Watty.
- Investors – Lightspeed, O.G. Venture Partners, Mark Zuckerberg & Priscilla Chan, Maria Sharapova, Will.i.am, Thierry Henry, Claudia Schiffer, Ari Emanuel, Tim Ferriss, among others.
- Board Additions – David Ofer (O.G. Venture Partners) slated to join the board pending regulatory approval.
Data & Statistics
- Over 100,000 scans completed in Sweden and the U.K. since 2023.
- More than 350,000 individuals on waitlists or registered for scans.
- Scan pricing: £299 in the U.K. (? $400) and 2,750 SEK in Sweden (? $285); U.S. pricing not disclosed.
- Unnamed sources cited by the Financial Times estimate a post-round valuation of ? $7 billion, up from $1.7 billion after the 2025 Series B.
Why It Matters
Neko Health’s AI-driven preventive model targets a market where traditional health systems intervene only after symptoms appear. If successful in the highly regulated U.S. environment, the company could accelerate adoption of routine, data-rich health monitoring, potentially reducing downstream treatment costs for chronic diseases such as diabetes, heart disease, and skin cancer.
Official Statements & Responses
Company press releases emphasize that the new funding will “take that mission to the U.S. for the first time, while continuing to invest in the research and technology that make prevention possible at scale.” The firm notes that its scans deliver results within minutes, followed by an in-person clinician review. Lightspeed partner Bejul Somaia highlighted the company’s “remarkable innovation and growth” and described Neko as “one of the most important healthcare companies of our generation.”
Criticism & Opposition
Medical commentators caution that frequent asymptomatic full-body scanning can generate false-positive results, leading to patient anxiety and unnecessary invasive follow-ups that strain health-care resources. Critics also point out that Neko’s internal efficacy data—such as the claim that three-quarters of returning members have “their flagged conditions safely under control”—has not been independently verified.
Conflicting Reports & Gaps
- Valuation: Neko Health did not disclose a valuation; unnamed Financial Times sources claim ? $7 billion, while the company remains silent.
- Pricing: U.S. scan costs have not been announced.
- Efficacy Data: Reported health-marker improvements are based on company-generated metrics without external validation.
Verbatim Quotes
- “With this round, we’re taking that mission to the U.S. for the first time, while continuing to invest in the research and technology that make prevention possible at scale,” — Hjalmar Nilsonne, Co-founder & CEO
- “I’m grateful to Neko for helping me discover this – I’m not sure how I would have otherwise.” — Alex Tew, Calm founder (X post)
- “Bejul Somaia, global partner, Lightspeed Venture Partners, said: “Over the past 18 months, Neko Health has demonstrated remarkable innovation and growth, attacking one of the largest markets in the world with breakthrough technology, proven consumer demand, and a clear path to global scale.” — Bejul Somaia, Global Partner, Lightspeed Venture Partners
- “We’ve known Hjalmar, Daniel and the founding team at Neko Health for years and have deep respect for their vision to redefine health for more than just the privileged few, on a global scale. They execute at a level few can match.” — Eyal Ofer, O.G. Venture Partners
- “I’ve invested in Neko because they offer beautiful simplicity, and only simplicity scales: you get a high-definition map of your biology in less than 60 minutes, explained by an unhurried doctor, all in one location and for £299.” — Tim Ferriss, Author
What’s Next
Neko Health has secured FDA clearance for several core scanning components and plans to open its New York clinic before year-end. David Ofer’s pending board appointment will formalize investor oversight as the company navigates U.S. regulatory and reimbursement landscapes.
